XML 98 R80.htm IDEA: XBRL DOCUMENT v3.22.0.1
Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2016
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Dec. 31, 2016
Derivative [Line Items]            
Revenues other than USD   48.00%        
Teva other comprehensive loss   $ 493.0        
Forward starting interest rate swaps and treasury lock agreements losses   37.0 $ 31.0 $ 29.0    
Interest Rate Swap Gain   5.0 3.0 6.0    
Deferred purchase asset   235.0 266.0      
Sold receivables   685.0 734.0 690.0    
Cash received on settlement of position     3.0      
Cost of sales [Member]            
Derivative [Line Items]            
Derivative, Gain on Derivative     31.0      
Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]            
Derivative [Line Items]            
Gain (Loss) on Derivative Instruments, Net, Pretax   31.0 [1] 0.5 14.0 [1]    
Senior Notes Due 2023 Two [Member]            
Derivative [Line Items]            
Notional amount hedge debt $ 3,000.0       $ 500.0 $ 500.0
Previously hedge debt rate         2.80% 2.80%
Settlement gain position   $ 10.0        
Cash received on settlement of position         $ 10.0  
Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss) 41.0          
Senior Notes Due 2022 [Member]            
Derivative [Line Items]            
Notional amount hedge debt $ 844.0          
Previously hedge debt rate 2.95%          
Senior Notes Due 2021 [Member]            
Derivative [Line Items]            
Notional amount hedge debt $ 450.0     $ 588.0    
Previously hedge debt rate 3.65%     3.65%    
Cash received on settlement of position       $ 95.0    
Senior Notes Due 2020 [Member]            
Derivative [Line Items]            
Cash received on settlement of position     $ 500.0      
Senior Notes Due 2021 Two [Member]            
Derivative [Line Items]            
Previously hedge debt rate       3.65%    
Cash received on settlement of position       $ 95.0    
[1] Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2021 and 2022. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In 2021, the positive impact from these derivatives recognized under revenues was $31 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.